BMKDF Stock Biomark Diagnostics (BMKDF, $0.36) Stochastic Oscillator left the overbought zone on January 07, 2026

GET DAILY SIGNALS

Get AI intraday signals

BMKDF - Biomark Diagnostics Inc.

Stochastic signal

View

Odds of DOWN Trend

Price: $0.3596

Daily change: $0 (0%)

Daily volume: 325

Capitalization: $36.5M

Industry: Medical Specialties

This is a signal that BMKDF's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. A.I.dvisor identified 66 similar cases where BMKDF's stochastic oscillator exited the overbought zone, and of them led to successful outcomes. Odds of Success:

BMKDF's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for BMKDF moved out of overbought territory on December 17, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Momentum Indicator moved below the 0 level on January 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMKDF as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BMKDF turned negative on December 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

The Aroon Indicator for BMKDF entered a downward trend on January 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMKDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BMKDF's P/B Ratio (56.497) is slightly higher than the industry average of (13.194). P/E Ratio (0.000) is within average values for comparable stocks, (125.887). BMKDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.949). BMKDF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). BMKDF's P/S Ratio (370.370) is very high in comparison to the industry average of (12.790).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.